Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 18;12:625699. doi: 10.3389/fphar.2021.625699

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Verbruggen, Sprimont, Bentea, Janssen, Gharib, Deneyer, De Pauw, Lara, Sato, Nicaise and Massie.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Long-term effects of chronic sulfasalazine (SAS) treatment. After a wash-out period of one week, body weight of xCT^+/+ (A) and xCT^−/− mice (B) was evaluated and plotted as the change compared to baseline (i.e. bodyweight at the start of the treatment). Distance travelled in the open field (OF) arena (C,D) or the elevated plus maze (EPM) (E,F), and velocity while exploring the EPM (G,H) were evaluated and represent long-term effects on locomotor function. Time spent in the center of the OF (I, J) or in the open arms of the EPM (K,L) was used as a parameter for anxiety-like behavior. For all tests, n = 8–10 xCT^+/+ mice/group and n = 10–11 xCT^−/− mice/group were used. Data are presented as mean ± SEM and analyzed using a Kruskal-Wallis test (*p < 0.05) followed by Dunn’s multiple comparisons for each dose of SAS compared to saline (^## p < 0.01).